'Reassuring Data' for Two Multiple Sclerosis Meds in Pregnan

Two studies report few complications from continuing ocrelizumab and natalizumab into pregnancy, with high live birth rates, a decline in elective abortions, and few major congenital abnormalities in newborns.

Related Keywords

Germany , Spain , Madrid , German , Celia Oreja Guevara , Sandra Thiel , Department Of Neurology , University Hospital San Carlos , Ruhr University Bochum , First Trimester Screening Program , Sclerosis Center , Johns Hopkins School Of Medicine , Research In Multiple Sclerosis , European Committee For Treatment , Josef Hospital , European Committee , Multiple Sclerosis , Multiple Sclerosis Center , German Multiple Sclerosis , Pregnancy Registry , Medscape Medical News , Angie Child Jelin , Johns Hopkins School , Multiple Sclerosis Ms , Us , Pregnancy , Postpartum , Postnatal , Uerperal , Spontaneous Abortion , Miscarriage , Premature Birth , Preterm Birth , Irth Preterm , First Trimester Pregnancy , Birth , Birth Defects , Selective Abortion , Multiple Sclerosis Relapse , S Relapse , Elapse Of Multiple Sclerosis , Elapse Of Ms , Newborn , Neonate , Europe , European , Hospitals , Inpatient Care , Multiple Scle ,